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Abstract The California Encephalitis Project (CEP), estab-
lishedin1998toexplore encephalitic etiologies,has identified
patients with N-methyl-D-aspartate receptor (NMDAR) anti-
bodies, the likely etiology of their encephalitis. This study
compares the presentation of such patients to those with viral
encephalitis, so that infectious disease clinicians may identify
individuals with this treatable disorder. Patients were
physician-referred, and standardized forms were used to
gather demographic, clinical, and laboratory data. Features of
anti-NMDAR+ patients were compared with the viral
encephalitides of enteroviral (EV), rabies, and herpes
simplex-1 (HSV-1) origins. Sixteen cases with confirmed
viral etiologies were all negative on NMDAR antibody
testing. Ten anti-NMDAR+ patients were profiled with a
median age of 18.5 years (range 11–31 years). None were
Caucasian. They had a characteristic progression with
prominent psychiatric symptoms, autonomic instability,
significant neurologic abnormalities, and seizures. Two had
a teratoma, and, of the remaining eight, four had serologic
evidence of acute Mycoplasma infection. The clinical and
imaging features of anti-NMDAR+ patients served to
differentiate this autoimmune disorder from HSV-1, EV,
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DOI 10.1007/s10096-009-0799-0and rabies. Unlike classic paraneoplastic encephalitis, anti-
NMDAR encephalitis affects younger patients and is often
treatable. The association of NMDAR antibodies in patients
with possible Mycoplasma pneumoniae infection warrants
further study.
Introduction
The causes of encephalitis are numerous, and most patients
undergo extensive testing to identify infectious etiologies.
However, other etiologies need to be considered. In the late
1960s, an association between limbic encephalitis and malig-
nancy was made, and, since then, a number of antineuronal
antibodies, such as the intracellular anti-Hu and anti-Ma, have
been discovered and found to be associated with a specific
array of cancers, as well as neuropsychiatric symptoms [1, 2].
More recently, antibodies to neuronal extracellular membrane
antigens have been recognized. One of these is the NR1
subunit of the N-methyl-D-aspartate receptor (NMDAR),
which was first identified in 2007. Unlike its classic
paraneoplastic counterparts, patients with this antibody may
or may not have an associated neoplasm, and often respond
to immunotherapy and tumor removal, if present [2].
The California Encephalitis Project (CEP) was initiated
in 1998 to identify the etiologic agents and define the
clinical and epidemiologic characteristics associated with
encephalitis. Over 3,000 cases have been referred to the
CEP, and many have been characterized into clinical
profiles [3]. In 2007, the CEP was notified that one referred
patient was diagnosed with an ovarian teratoma associated
with NMDAR antibodies. This case, in combination with
previous experience with cases of a similar phenotype and
unclear etiology, as well as the increasing recognition of
anti-NMDAR encephalitis worldwide, led us to a collabo-
rative work with the University of Pennsylvania focused on
the identification of similar cases within the context of CEP
referrals [2, 4–7]. The purpose herein is to describe patients
within the CEP that tested positive for the NMDAR
antibody and compare them with patients that had a
confirmed viral etiology, so that infectious disease physi-
cians can more readily identify those affected with this new,
potentially treatable, immune-mediated disorder.
Methods
Patient selection/enrollment
Specimens are referred to the CEP by their treating
physicians for diagnostic testing. Patients are required to
be immunocompetent, at least 6 months of age, and must
meet the CEP case definition of encephalitis, by which
patients must be hospitalized with encephalopathy with at
least one of the following: fever, seizure, focal neurologic
findings, cerebrospinal fluid (CSF) pleocytosis, or electro-
encephalographic or neuroimaging findings consistent with
encephalitis. A standardized case history form is submitted by
the referring physician with patient information on exposures,
travel, laboratory findings, and clinical and demographic
characteristics. This study was approved by an ethical stand-
ards committee, and subjects signed a consent form prior to
NMDAR antibody testing.
CEP core testing
CSF, respiratory specimens, and acute- and convalescent-
phase serum specimens are submitted and tested for 16
potential infectious agents of encephalitis, including her-
pesviruses, enteroviruses, arboviruses, respiratory viruses,
and Mycoplasma pneumoniae [3].
Once the CEP became aware of the occurrence of anti-
NMDAR+ encephalitis, collaboration with the University
of Pennsylvania was established to facilitate the recognition
and testing of anti-NMDAR+ cases within the CEP, as
follows: retrospective testing of patients who had idiopathic
encephalitis, along with dyskinesias or movement disor-
ders; and prospective referral of cases based on similar
syndromic features. Testing for NMDAR antibodies was
performed as previously described [6]. Samples from a
limited number of patients with confirmed viral etiologies
including enteroviral (EV), rabies, and herpes simplex-1
(HSV-1), varicella zoster virus, and rabies were selected
and tested for NMDAR antibodies.
Data analysis
Demographic, clinical, and laboratory data from anti-
NMDAR+ patients were compared with data from enceph-
alitis patients with confirmed EV and HSV-1, since these
are the most commonly identified viral etiologies within the
CEP. Rabies virus cases were also included for comparison
because this diagnosis was strongly suspected by referring
physicians in several cases that were ultimately found to be
NMDAR antibody positive. Categorical data were analyzed
using the Chi-square test, and continuous data were
subjected to the Kruskal-Wallis test. Statistical significance
was defined as P<0.05.
Results
Characteristics of anti-NMDAR+ cases
Of the 20 cases tested, ten anti-NMDAR+ cases were
identified; two patients were identified by retrospective
1422 Eur J Clin Microbiol Infect Dis (2009) 28:1421–1429testing and eight cases were identified prospectively. All ten
patients were negative for viral studies, but four had a
positive serum Mycoplasma IgM. The demographic, clin-
ical, laboratory, and imaging findings of the ten cases are
summarized in Table 1, while the frequencies are found in
Table 2. The median age was 18.5 years (range 11–31 years),
and none were of Caucasian descent, while there was a
predilection for Asians/Pacific Islanders (50%). Although
60% of patients presented with apparently benign symptoms,
all had returned with more severe symptomatology within
days. Nearly all patients demonstrated personality changes,
and the majority (70%) displayed extreme irritability. Psychi-
atric symptoms were common and manifested earlier in the
course of the illness, often at presentation. Psychotic
symptoms were noted in 68% of subjects, with all of these
patients experiencing hallucinations, particularly of the
auditory nature. Other schizophrenia-like symptoms, includ-
ing flat affect and disorganized thinking, were reported in
three patients. Two subjects presented with seizures, and an
additional 60% developed seizures after hospitalization, often
of the tonic-clonic type, but sometimes in combination with
focal episodes. Mental status changes were nearly universal,
andcareinthe intensivecareunit(ICU)wasrequired;patients
had a median Glasgow Coma Scale (GCS) score of 8.
Choreoathetoid movements, ataxic gait, cranial nerve
abnormalities, repetitive orofacial movements, and aphasia
were each reported in around half of the patients. Subjects
suffered from various combinations of neurologic findings,
but 90% of patients experienced at least two or more
abnormalities, while 60% demonstrated three or more
abnormal neurologic findings. Sixty percent of those with
orofacial dyskinesias had movements limited to the mouth
alone, including lip smacking, tongue protrusion, and
bruxism, each unassociated with a seizure focus on EEG
when concurrent motor activity was present. None of the
patients were believed to acquire these findings as a result of
anti-psychotic medications, but, in one case, the medication
did precede the development of symptoms. Choreoathetoid
movements and dyskinesias were also highly variable from
p a t i e n tt op a t i e n t ,w i t hn od i s t i n c tp a t t e r ni nt e r m so fr a t eo r
rhythm (Table 1). Dysautonomia was nearly ubiquitous in
anti-NMDAR+ patients, observed in 89% of cases. Tachycar-
dia and bradycardia, blood pressure lability, hyperthermia,
hypoventilation, and/or apnea were each reported in most
patientswithautonomicinstability.Manypatientsexperienced
three or more types of instability, making these symptoms
prominent clinical manifestations (Table 1).
Laboratory, EEG, and neuroimaging findings
The majority of anti-NMDAR+ patients (89%) demonstrated
a lymphocytic pleocytosis duringthe course of illness,with a
median CSF white blood cell (WBC) count of 26/μlo n
presentation. The median CSF protein concentrations were
elevated, but the CSF glucose was often within normal
limits. EEG monitoring revealed diffuse slowing almost
universally. Focal epileptic activity was uncommon (10%)
and paroxysmal discharges were not observed (Table 1).
Computedtomography(CT) rarely revealedabnormalities.
While magnetic resonance imaging (MRI) was normal on
admission in all patients, changes were demonstrated in 40%
of subjects on follow-up studies. However, the findings on
MRI, for both fluid-attenuated inversion recovery (FLAIR)
and T2-weighted images, were not consistent from patient to
patient. Periventricular white matter demyelination and other
nonspecific findings were observed in one case, and temporal
lobe abnormalities were notable in others. Nonspecific
abnormalities, or, often, no abnormality at all, appeared to be
the standard for these patients.
Comparison of anti-NMDAR encephalitis with viral
encephalitis
Samples from 16 cases with confirmed viral etiologies were
all negative upon testing for anti-NMDAR antibodies.
Comparison of anti-NMDAR+ patients to those with viral
etiologies of encephalitis revealed significant differences
(Table 2). Viral cases were not disproportionately common
among Asians or Pacific Islanders (P<0.05 for HSV-1, EV,
and rabies-associated encephalitides). Psychosis was signif-
icantly less common in all viral groups with frequencies of 0
to 2% (P<0.0001), and the presence of hallucinations was
also less likely (P<0.05 for all groups). Personality changes,
though more frequent in HSV-1 and rabies virus patients,
were seen significantly less often in encephalitic subjects
with a viral etiology (P<0.0001 for all groups). Seizure
activity was observed less often among virus-infected
individuals, though not statistically less so among those with
HSV-1 encephalitis (P<0.001 for EV and rabies cases).
Laboratory studies revealed that the CSF WBC median
was higher in those with EV and HSV-1 (90 and 56 cells
per μl, respectively) than in those with anti-NMDAR+
encephalitis (22 cells per μl). Rabies virus cases rarely
demonstrated CSF pleocytosis, with a median count of 3.5
cells per μl( P<0.05). The median CSF protein concen-
trations were significantly higher in those with viral causes,
with the exception of those with rabies (65 mg/dl in HSV-1
and 54 mg/dl in EV vs. 28 mg/dl in anti-NMDAR+ patients;
P<0.05 for both), but the CSF glucose concentrations did
not differ. Temporal lobe changes on neuroimaging were
more common in patients with HSV-1 (27 and 69%,
respectively; P<0.05).
Overall, viral causes, and especially EV encephalitis,
appeared to cause fewer severe complications, including a
lower rate of alteration in consciousness (36 vs. 50%), ICU
admission (33 vs. 80%), and intubation (5 vs. 60%).
Eur J Clin Microbiol Infect Dis (2009) 28:1421–1429 1423T
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NMDAR (n = 10) Confirmed HSV-1
cases (n = 52)
Confirmed enterovirus
cases (n = 85)
Confirmed rabies
cases (n =6 )
Demographics
Age, median, years 18.5 (range 11–31) 46.0 (range 0–89) 14.0 (range 0–75) 38.5 (range 11–72)
Gender
Male 4 (40%) 26 (50%) 52 (61%) 6 (100%)
Female 6 (60%) 26 (50%) 33 (39%) 0
Ethnicity
White, Hispanic 2 (20%) 8 (15%) 26 (31%) 1 (17%)
White, non-Hispanic 0 27 (52%) 30 (35%) 1 (17%)
Black 3 (30%) 2 (4%) 7 (8%) 0
Asian/Pacific Islander 5 (50%) 3 (6%) 10 (12%) 2 (33%)
Other/unknown 0 12 (23%) 11 (13%) 2 (33%)
Clinical findings
General symptoms
Fever 7 (70%) 46 (88%) 63 (74%) 4 (67%)
GI 5 (50%) 19 (36%) 35 (41%) 5 (83%)
URI 1 (10%) 11 (21%) 24 (28%) 4 (67%)
Rash 0 3 (6%) 15 (18%) 0
Intubation 6 (60%) 8 (15%) 4 (5%) 5 (83%)
ICU admission 8 (80%) 30 (58%) 28 (33%) 4 (67%)
Seizures 8 (80%) 30 (58%) 24 (28%) 2 (33%)
Coma 3 (30%) 8 (15%) 5 (6%) 5 (83%)
Died 1 (10%) 9 (17%) 5 (6%) 6 (100%)
Neurologic symptoms
Altered consciousness 5 (50%) 32 (62%) 31 (36%) 4 (67%)
Ataxia 6 (60%) 7 (13%) 23 (27%) 0
Focal neurologic signs 6 (60%) 17 (33%) 24 (28%) 2 (33%)
Stiff neck 3 (30%) 16 (31%) 27 (32%) 0
Cranial nerve abnormality 3 (30%) 0 3 (4%) 0
Psychiatric symptoms
Hallucinations 6/9 (67%) 8 (15%) 9 (11%) 1 (17%)
Psychosis 6/9 (67%) 1 (2%) 2 (2%) 0
Personality change 10 (100%) 15 (29%) 7 (8%) 2 (33%)
Irritability 7 (70%) 11 (21%) 29 (34%) 1 (17%)
Laboratory data
a
CSF
WBC, median (range), per mm
3 22 (range 3–170) 90 (range 0–110) 55.5 (range 0–1,332) 3.5 (range 0–10)
Protein, mg/dL 28.5 (range 21–220) 65 (range 6–297) 54 (range 16–881) 35 (range 32–172)
Glucose, mg/dL 62 (range 55–72) 68 (range 39–112) 66 (range 27–159) 65 (range 60–110)
Neuroimaging abnormality
a
MRI
Temporal lobe 0 36 (69%) 4 (5%) 0
Hydrocephalus 0 1 (2%) 0 0
White matter involvement 1 (10%) 4 (8%) 4 (5%) 0
Cerebral edema 0 1 (2%) 0 0
CT
Temporal lobe 0 14 (27%) 0 0
Hydrocephalus 0 1 (2%) 3 (4%) 0
White matter involvement 0 1 (2%) 2 (2%) 0
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NMDAR encephalitis, this is a severe disorder that may
result in death. In the current study, 10% of anti-NMDAR+
patients died of this disorder, a number that is higher than
those who died of EV (6%), although lower than the
mortality associated with HSV-1 (19%) and rabies (100%).
Discussion
When patients present with clinical features of encephalitis,
viral etiologies are among the primary considerations in
establishing a diagnosis, with HSV-1 and EV being among
the most common offending agents [3, 8, 9]. Viral testing
can be time consuming and, if it is unable to reveal the
cause for the patient’s condition, can leave clinicians
confounded as to how to proceed with further testing or
treatment. Autoimmune etiologies should be considered in
the differential diagnosis, even at initial presentation.
Despite the small sample of anti-NMDAR+ patients,
there are clinical features that appear to be common in
patients with anti-NMDAR+ encephalitis, and which
correlate with those reported in other case series describing
similar encephalitic patients. While prodromal symptoms
were not highly patterned in the patients in this study,
others have noted a consistent ‘flu-like’ viral illness prior to
or with initial presentation, though most patients herein did
report fever and headache [2, 10–18]. The progression of
illness noted in this series did, however, resemble that
described in other studies.
Anti-NMDAR+ encephalitic patients appear to develop a
somewhat predictable course of illness, during which a
number of symptoms are frequently observed. Psychiatric
symptoms manifest early in the course of illness, and
patients are likely to display schizophrenia-like behaviors,
such as psychosis and hallucinations. This is consistent
with the observation that NMDAR antagonists can cause
healthy individuals to develop schizophrenia-like symp-
toms [19–21]. A newly published study also revealed that
antibodies from patients with anti-NMDAR receptor en-
cephalitis cause a dramatic decrease in the number of
NMDAR postsynaptic clusters in neuronal cultures, sug-
gesting a decrease in NMDAR function [22]. Behavior and
personality changes, sometimes with notable aggression,
appear to be additionally remarkable in patients with this
form of encephalitis [2, 10–18, 22]. Continued decompen-
sation is the norm in these patients, with most requiring
intensive care monitoring and possibly ventilatory support.
Hypoventilation, in particular, has been described as a
significant feature of this illness, affecting 66% of those in a
100-patient series [22]. Other neurologic symptoms also
develop in nearly every patient, including dystonias, orofacial
movements, particularly oral dyskinesias, and choreoatheto-
sis; none of these have epileptic origins. However, seizures
themselves, often of a tonic-clonic nature, are common,
with no correlative epileptiform discharges that permitted
localization on EEG [2, 16–18, 22]. Mental status changes,
though seen in some patients at presentation, consistently
developed later in the course of illness, with many patients
becoming non-responsive and non-verbal, and displaying
low GCS scores. Autonomic instability is almost always
observed.
Specific demographic characteristics were notable
among our cases and, at times, possibly as a result of the
small anti-NMDAR+ sample size, at odds with previous
reports. There were a larger number of males in our series,
which is likely a result of the selection process. However, it
may also be that males have been less readily recognized
with this diagnosis, as there have been inconsistent
associations with concurrent neoplasms, making clinicians
hesitant to attribute symptoms to this specific cause. It is
not clear whether or not these individuals would ultimately
be found to have tumors, or whether, as with other
autoimmune encephalitides (e.g., that are associated with
Table 2 (continued)
NMDAR (n = 10) Confirmed HSV-1
cases (n = 52)
Confirmed enterovirus
cases (n = 85)
Confirmed rabies
cases (n =6 )
Cerebral edema 0 0 0 0
EEG
Slowing 8 (80%) 9 (17%) 7 (8%) 2 (33%)
Epileptiform activity 1 (10%) 7 (13%) 2 (2%) 0
PLEDs 0 4 (8%) 1 (1%) 0
CSF = cerebrospinal fluid; WBC = white blood cell; MRI =magnetic resonance imaging; CT= computed tomography; EEG=electroencephalogram;
PLEDs = periodic lateralized epileptiform discharges; ICU = intensive care unit
Denominators used in the calculations may vary, depending on the available data
aData are from initial neuroimaging studies or initial lumbar puncture
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of patients simply did not harbor neoplasms [23, 24]. This
is often difficult to ascertain, as many paraneoplastic
syndromes can precede the discovery of associated tumor
by years [2].
Patients were also more likely to be of Asian or Pacific
Islander descent, a finding suggested by a recent publication
from Japan [15]. This was surprising, given that teratomas,
which are the most common tumors associated with anti-
NMDAR encephalitis, demonstrate no racial bias, though
malignant ones are more common among Asians [25].
In the present series, the median age was younger than
that in prior studies, in which a higher percentage of
patients with teratomas were identified [2, 7, 10–18, 22].
Given the small number of subjects, it is difficult to
ascertain whether the true median age for this entity is as
low as 18.5 years, but it is notable that a number of subjects
in the current series were children. Those as young as
5 years of age have been described elsewhere, and the
median age appears to be distinctly younger than that seen
among those with classic paraneoplastic syndromes [2, 14,
16]. Only 20% of those examined herein had ovarian
teratomas, and, interestingly, of those without tumors, 50%
had positive Mycoplasma IgM serologies. As previously
reported, the significance of an isolated positive M.
pneumoniae serum IgM, especially without signs of
Mycoplasma IgG change or polymerase chain reaction
(PCR) positivity is unknown [26]. On average, only about
10% of CEP patients have positive serology for M.
pneumoniae, making this percentage higher than generally
expected. This observation lends itself to the speculation that
anti-NMDAR+ patients may develop encephalitis as a result
of a post-infectious, antibody-mediated process such as that
observed in Sydenham’s chorea or other pediatric autoim-
muneneuropsychiatricdisordersassociatedwithstreptococcal
infections (PANDAs) in which antistreptococcal-antineuronal
antibodies are thought to destroy healthy nervous system cells
which serve as molecular mimics [27–29]. Because the
association with M. pneumoniae is not fully understood,
clinicians should be cautioned against accepting M. pneumo-
niae as the sole explanation for an encephalitic illness,
especially if this diagnosis is based on a single IgM test.
The differentiation of anti-NMDAR+ associated encepha-
litis from encephalitis of viral origin on clinical grounds alone
is difficult, although our study reveals that there may be some
useful clues. HSV-1 patients will typically be older than anti-
NMDAR+ patients, and are less likely to display severe
psychiatric disturbances and schizophrenia-like symptoms.
HSV-1 encephalitis patients are also not as likely to display
combinations of movement disorders, such as choreoathetosis
and orofacial dyskinesias, as those with anti-NMDAR
encephalitis [28, 29]. Autonomic instability is not a
predominant feature of HSV. Focal EEG abnormalities of
the temporal lobe may also point to a viral etiology and, of
course, a positive HSV PCR in the CSF is a defining feature
of herpes simplex encephalitis [3, 9, 30, 31].
EV encephalitis, like HSV-1 encephalitis, is generally
associatedwitha higher WBC countand proteinconcentration
in the CSF when compared to patients with anti-NMDAR+
encephalitis.Neuroimagingisnonspecificinthesepatients, but
symptomatology can play a substantial role in differentiating
these two etiologies because psychiatric and focal neurologic
findings will be much less likely. Patients with EV-associated
encephalitis are less apt to decompensate and become non-
responsive and unable to verbally communicate. Autonomic
instability with subsequent ventilatory support plays a much
moresubtlerole in EV-affected individualsand, aswith HSV-1
encephalitis, EV can be detected in the CSF [31, 32].
Rabies virus cases pose a particular diagnostic challenge
because behavioral symptoms can be as prominent as they
are with anti-NMDAR encephalitis. Exposure history, along
with diagnostic testing for rabies, is of great value. Typically,
more than one diagnostic test will be required to diagnose
rabies encephalitis in antemortem patients, while a brainstem
biopsy alone is required in post-mortem individuals [33].
Thestudy resultsdomerit afew additional considerations.
Reports of cranial nerve abnormalities, ataxic gait, and
aphasic findings, obtained from CEP questionnaires, can be
subjective in their interpretation. For example, it may be that
facial nerve dysfunction and ocular deviations were, in
reality, of central origin, as oculogyric crises and facial
dystonias have been reported to occur in anti-NMDAR+
patients [16, 22]. Yet, despite their variable interpretation,
gait, facial, and verbal abnormalities, whether of central
origin or not, are noted in many cases and can assist in
suggesting a diagnosis. Furthermore, though many of our
positive confirmed viral cases were not tested for the
presence of NMDAR antibodies, samples from 16 patients
within the CEP cohort with confirmed viral etiologies were
negative for NMDAR antibodies, and based on previous
work by Dalmau et al. [22], the antibody is both highly
sensitive and specific. It binds to a distinct region of the
NMDAR. Although viral encephalitis, stroke, chronic
epilepsy, and lupus have been associated with NMDAR
antibodies, the region of the NR1 portion of the receptor to
which the NMDAR antibodies bind appears to be uniquely
associated with anti-NMDAR encephalitis, as opposed to
other conditions.
The management of anti-NMDAR+ encephalitis can
prove to be very effective and involves the identification
and treatment of the tumor, along with immunotherapy. In a
series of 100 cases, 91 were women, and 63% had a tumor,
primarily an ovarian teratoma. Only 2 of the 9 men had a
tumor (one teratoma of the testis and one small-cell lung
cancer). Patients with prompt tumor removal and immuno-
therapy (e.g., steroids) had better outcomes and fewer
Eur J Clin Microbiol Infect Dis (2009) 28:1421–1429 1427neurological relapses than those whose tumor was not
treated or who had no tumor. Nevertheless, patients of the
latter groups also responded to immunotherapy. Overall,
75% recovered or had mild deficits, while 18% had severe
deficits, with 7% dying as a result of the encephalitis [22].
Larger studies are needed to estimate the true incidence of
anti-NMDAR encephalitis among cases that, after extensive
viral screenings, have previously been considered as ‘idio-
pathic encephalitis,’‘ encephalitis of unclear etiology,’ or
‘encephalitis lethargica.’ Among these, our study shows that
certain clinical profiles such as “encephalitis with dyskinesias
or abnormal movements” are likely to be frequently related to
anti-NMDAR encephalitis. Of the approximately 20 samples
tested, ten (50%) were positive, suggesting that this syndrome
is a relatively common cause of encephalitis and should be
routinely considered in patients with characteristic clinical
features. Moreover, although the set of symptoms associated
with anti-NMDAR encephalitis is highly predictable and the
frequency of dyskinesias very high [34], our study likely
underestimates the true incidence of this disorder by focusing
on a profile based on ‘dyskinesias or abnormal movements,’
and excluding milder forms or ‘formes frustes,’ such as those
associated with ‘psychiatric symptoms and seizures’ with
minimal or absent abnormal movements [35].
Anti-NMDAR+ encephalitis is a recognizable, diagnos-
able, and treatable illness. Patients, in general, will have good
outcomes, particularly with aggressive and prompt therapy.
Clinicians must be aware of this condition, especially when
evaluating patients with encephalitis.
Acknowledgments We thank the laboratory staff of the Viral and
Rickettsial Disease Laboratory and Microbial Disease Laboratory for
performing the diagnostic testing. We also thank the clinicians who
referred cases to the California Encephalitis Project (CEP).
Financial support was obtained from the Centers for Disease
Control and Prevention Emerging Infections Program *U50/
CCU915546-09).09 (CG), and there was additional support, in part,
from the National Institute of Health 2RO1CA89054-06A2 (JD).
There are no conflicts of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Gultekin SH, Rosenfeld MR, Voltz R et al (2000) Paraneoplastic
limbic encephalitis: neurological symptoms, immunological
findings and tumour association in 50 patients. Brain 123:1481–
1494
2. Tüzün E, Dalmau J (2007) Limbic encephalitis and variants:
classification, diagnosis and treatment. Neurologist 13:261–271
3. Glaser CA, Honarmand S, Anderson LJ et al (2006) Beyond
viruses: clinical profiles and etiologies associated with encepha-
litis. Clin Infect Dis 43:1565–1577
4. Seki M, Suzuki S, Iizuka T et al (2008) Neurological response to
early removal of ovarian teratoma in anti-NMDAR encephalitis. J
Neurol Neurosurg Psychiatry 79(3):324–326
5. Iizuka T, Sakai F (2008) Anti-NMDA receptorencephalitis—clinical
manifestations and pathophysiology. Brain Nerve 60:1047–1060
6. Dalmau J, Tüzün E, Wu HY et al (2007) Paraneoplastic anti-N-
methyl-D aspartate receptor encephalitis associated with ovarian
teratoma. Ann Neurol 61:25–36
7. Sansing LH, Tüzün E, Ko MW et al (2007) A patient with
encephalitis associated with NMDA receptor antibodies. Nat Clin
Pract Neurol 3:291–296
8. Chaudhuri A, Kennedy PG (2002) Diagnosis and treatment of
viral encephalitis. Postgrad Med J 78:575–583
9. Whitley RJ, Gnann JW (2002) Viral encephalitis: familiar
infections and emerging pathogens. Lancet 359:507–513
10. Vitaliani R, Mason W, Ances B et al (2000) Paraneoplastic
encephalitis, psychiatric symptoms, and hypoventilation in ovarian
teratoma. Ann Neurol 58:594–604
11. Koide R, Shimizu T, Koike K et al (2007) EFA6A-like antibodies
in paraneoplastic encephalitis associated with immature ovarian
teratoma: a case report. J Neurooncol 81:71–74
12. Stein-Wexler R, Wootton-Gorges SL, Greco CM et al (2005)
Paraneoplastic limbic encephalitis in a teenage girl with an
immature ovarian teratoma. Pediatr Radiol 35:694–697
13. Bataller L, Kleopa KA, Wu GF et al (2007) Autoimmune limbic
encephalitis in 39 patients: immunophenotypes and outcomes. J
Neurol Neurosurg Psychiatry 78:381–385
14. Rosenbaum T, Gärtner J, Körholz D et al (1998) Paraneoplastic
limbic encephalitis in two teenage girls. Neuropediatrics 29:159–162
15. Iizuka T, Sakai F, Ide T et al (2008) Anti-NMDA receptor
encephalitis in Japan: long-term outcome without tumor removal.
Neurology 70:504–511
16. Yuasa T, Nemoto H, Kimura A (2003) Four cases of acute
reversible limbic encephalitis predominantly affecting juvenile
female and presenting with psychosis with minimal changes on
MRI. Neurol Med 59:45–50
17. Lee ACW, Ou Y, Lee WK et al (2003) Paraneoplastic limbic
encephalitis masquerading as chronic behavioural disturbance in
an adolescent girl. Acta Paediatr 92:506–509
18. Muni RH, Wennberg R, Mikulis DJ et al (2004) Bilateral
horizontal gaze palsy in presumed paraneoplastic brainstem
encephalitis associated with a benign ovarian teratoma. J Neuro-
ophthalmol 24:114–118
19. Olney JW, Newcomer JW, Farber NB (1999) NMDA receptor
hypofunction model of schizophrenia. J Psychiatr Res 33:523–533
20. Coyle JT, Tsai G, Goff D (2003) Converging evidence of NMDA
receptor hypofunction in the pathophysiology of schizophrenia.
Ann N Y Acad Sci 1003:318–327
21. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of
phencyclidine: from NMDA receptor hypofunction to the dopamine
hypothesisofschizophrenia.Neuropsychopharmacology20:201–225
22. Dalmau J, Gleichman AJ, Hughes EG et al (2008) Anti-NMDA-
receptor encephalitis: case series and analysis of the effects of
antibodies. Lancet Neurol 7:1091–1098
23. Vincent A, Buckley C, Schott JM et al (2004) Potassium channel
antibody-associated encephalopathy: a potentially immunotherapy-
responsive form of limbic encephalitis. Brain 127:701–712
24. Thieben MJ, Lennon VA, Boeve BF et al (2004) Potentially
reversible autoimmune limbic encephalitis with neuronal potassi-
um channel antibody. Neurology 62:1177–1182
25. Zalel Y, Piura B, Elchalal U et al (1996) Diagnosis and
management of malignant germ cell ovarian tumors in young
females. Int J Gynaecol Obstet 55:1–10
26. Christie LJ, Honarmand S, Talkington DF et al (2007) Pediatric
encephalitis: what is the role of Mycoplasma pneumoniae?
Pediatrics 120:305–313
1428 Eur J Clin Microbiol Infect Dis (2009) 28:1421–142927. Rose NR (1998) The role of infection in the pathogenesis of
autoimmune disease. Semin Immunol 10:5–13
28. Swedo SE (1994) Sydenham’s chorea. A model for childhood
autoimmune neuropsychiatric disorders. JAMA 272:1788–1791
29. Murphy ML, Pichichero ME (2002) Prospective identification and
treatment of children with pediatric autoimmune neuropsychiatric
disorderassociated withgroup A streptococcal infection (PANDAS).
Arch Pediatr Adolesc Med 156:356–361
30. Redington JJ, Tyler KL (2002) Viral infections of the nervous
system, 2002: update on diagnosis and treatment. Arch Neurol
59:712–718
31. Hinson VK, Tyor WR (2001) Update on viral encephalitis. Curr
Opin Neurol 14:369–374
32. Muir P, van Loon AM (1997) Enterovirus infections of the central
nervous system. Intervirology 40:153–66
33. Plotkin SA (2000) Rabies. Clin Infect Dis 30(1):4–12
34. Florance NR, Davis RL, Lam C et al (2009) Anti-NMDA receptor
encephalitis in children and adolescents. Ann Neurol (in press).
doi:10.1002/ana.21756
35. Niehusmann P, Dalmau J, Rudlowski C et al (2009) Diagnostic
value of N-methyl-D-aspartate receptor antibodies in women with
new-onset epilepsy. Arch Neurol 66:458–464
Eur J Clin Microbiol Infect Dis (2009) 28:1421–1429 1429